This atlas presents not only the differential diagnosis but also the detailed morphologic, immunophenotypic, and especially genetic characteristics of the majority of hematolymphoid malignancies. An expert hematopathologist here provides a valuable resource to understand, use, or interpret one or more of these diagnostic modalities with confidence. This new edition has a compact format with up-to-date information - especially on genetic aspects - and will be an indispensable reference for all professionals in the specialty. *Provides an unrivalled visual resource for differential diagnosis in neoplastic hematopathology *Enables specialist and trainee oncologists and pathologists alike to understand, use, and interpret diagnostic modalities with confidence *Supplies quick access to information via tables, algorithms, and composite figures

Cytogenetics, fluorescence in situ hybridization (FISH) and molecular tests, especially polymerase chain reaction (PCR), play an important role in the management of patients with hematologic malignancies by helping to establish the diagnosis, as well as predict prognosis, response to treatment and disease progression. Chromosomal and molecular abnormalities provide the most reliable criteria for classification of hematopoietic tumors and often comprise the basis for targeted therapy.

Cytogenetics, FISH and Molecular Testing in Hematologic Malignancies, provides a review of chromosomal and molecular changes in hematologic malignancies and correlates the karyotypic and genetic abnormalities with morphology, immunophenotype and clinical data. With over 180 figures and diagnostic algorithms, this text is essential reading for all pathologists, hematopathologists, hematologic oncologists, cytogenetists, cytogenetic technologists and cell biologists.

This fourth edition presents an updated and expanded text and illustrations to reflect continued morphologic, immunophenotypic, and especially molecular advances in the field of neoplastic hematology, mostly due to the rapidly expanding application of next-generation sequencing. Those advances not only allow a more reliable diagnosis of the majority of tumors and identification of early changes such as monoclonal B-cell lymphocytosis or clonal hematopoiesis of indeterminate potential (CHIP), but also in many cases identify mutations or phenotypic changes in tumors that can be targeted by mutation-specific or antigen-specific drugs. This edition incorporates the updated WHO classification of hematopoietic tumors and new immunophenotypic and molecular markers to provide a thorough pathologic overview of hematologic neoplasms while focusing on flow cytometric features. Special emphasis has been put on hematological neoplasms with crucial clinical significance such as acute promyelocytic leukemia, other acute leukemias, and difficult areas in flow cytometry. Flow cytometric features in AML, MDS, CMML, CLL and measurable residual disease were significantly expanded. There are many new comparative tables, illustrations, and diagrams of algorithmic approaches.